These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

323 related articles for article (PubMed ID: 35668304)

  • 1. First-line pembrolizumab + chemotherapy in Japanese patients with advanced/metastatic esophageal cancer from KEYNOTE-590.
    Kojima T; Hara H; Tsuji A; Yasui H; Muro K; Satoh T; Ogata T; Ishihara R; Goto M; Baba H; Nishina T; Han S; Sakata T; Yatsuzuka N; Doi T; Kato K
    Esophagus; 2022 Oct; 19(4):683-692. PubMed ID: 35668304
    [TBL] [Abstract][Full Text] [Related]  

  • 2. First-line pembrolizumab plus chemotherapy for advanced/metastatic esophageal cancer: 1-year extended follow-up in the Japanese subgroup of the phase 3 KEYNOTE-590 study.
    Kato K; Kojima T; Hara H; Tsuji A; Yasui H; Muro K; Satoh T; Ogata T; Ishihara R; Goto M; Baba H; Nishina T; Han S; Iwakami K; Yatsuzuka N; Doi T
    Esophagus; 2024 Jul; 21(3):306-318. PubMed ID: 38607538
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Pembrolizumab plus chemotherapy versus chemotherapy alone for first-line treatment of advanced oesophageal cancer (KEYNOTE-590): a randomised, placebo-controlled, phase 3 study.
    Sun JM; Shen L; Shah MA; Enzinger P; Adenis A; Doi T; Kojima T; Metges JP; Li Z; Kim SB; Cho BC; Mansoor W; Li SH; Sunpaweravong P; Maqueda MA; Goekkurt E; Hara H; Antunes L; Fountzilas C; Tsuji A; Oliden VC; Liu Q; Shah S; Bhagia P; Kato K;
    Lancet; 2021 Aug; 398(10302):759-771. PubMed ID: 34454674
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Efficacy and Safety of Pembrolizumab for Heavily Pretreated Patients With Advanced, Metastatic Adenocarcinoma or Squamous Cell Carcinoma of the Esophagus: The Phase 2 KEYNOTE-180 Study.
    Shah MA; Kojima T; Hochhauser D; Enzinger P; Raimbourg J; Hollebecque A; Lordick F; Kim SB; Tajika M; Kim HT; Lockhart AC; Arkenau HT; El-Hajbi F; Gupta M; Pfeiffer P; Liu Q; Lunceford J; Kang SP; Bhagia P; Kato K
    JAMA Oncol; 2019 Apr; 5(4):546-550. PubMed ID: 30570649
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Pembrolizumab or pembrolizumab plus chemotherapy versus standard of care chemotherapy in patients with advanced gastric or gastroesophageal junction adenocarcinoma: Asian subgroup analysis of KEYNOTE-062.
    Satake H; Lee KW; Chung HC; Lee J; Yamaguchi K; Chen JS; Yoshikawa T; Amagai K; Yeh KH; Goto M; Chao Y; Lam KO; Han SR; Shiratori S; Shah S; Shitara K
    Jpn J Clin Oncol; 2023 Mar; 53(3):221-229. PubMed ID: 36533429
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Pembrolizumab versus chemotherapy for patients with esophageal squamous cell carcinoma enrolled in the randomized KEYNOTE-181 trial in Asia.
    Cao Y; Qin S; Luo S; Li Z; Cheng Y; Fan Y; Sun Y; Yin X; Yuan X; Li W; Liu T; Hsu CH; Lin X; Kim SB; Kojima T; Zhang J; Lee SH; Bai Y; Muro K; Doi T; Bai C; Gu K; Pan HM; Bai L; Yang JW; Cui Y; Lu W; Chen J
    ESMO Open; 2022 Feb; 7(1):100341. PubMed ID: 34973513
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Effect of Camrelizumab vs Placebo Added to Chemotherapy on Survival and Progression-Free Survival in Patients With Advanced or Metastatic Esophageal Squamous Cell Carcinoma: The ESCORT-1st Randomized Clinical Trial.
    Luo H; Lu J; Bai Y; Mao T; Wang J; Fan Q; Zhang Y; Zhao K; Chen Z; Gao S; Li J; Fu Z; Gu K; Liu Z; Wu L; Zhang X; Feng J; Niu Z; Ba Y; Zhang H; Liu Y; Zhang L; Min X; Huang J; Cheng Y; Wang D; Shen Y; Yang Q; Zou J; Xu RH;
    JAMA; 2021 Sep; 326(10):916-925. PubMed ID: 34519801
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Sintilimab versus placebo in combination with chemotherapy as first line treatment for locally advanced or metastatic oesophageal squamous cell carcinoma (ORIENT-15): multicentre, randomised, double blind, phase 3 trial.
    Lu Z; Wang J; Shu Y; Liu L; Kong L; Yang L; Wang B; Sun G; Ji Y; Cao G; Liu H; Cui T; Li N; Qiu W; Li G; Hou X; Luo H; Xue L; Zhang Y; Yue W; Liu Z; Wang X; Gao S; Pan Y; Galais MP; Zaanan A; Ma Z; Li H; Wang Y; Shen L;
    BMJ; 2022 Apr; 377():e068714. PubMed ID: 35440464
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Tislelizumab Plus Chemotherapy as First-line Treatment for Advanced Esophageal Squamous Cell Carcinoma and Gastric/Gastroesophageal Junction Adenocarcinoma.
    Xu J; Bai Y; Xu N; Li E; Wang B; Wang J; Li X; Wang X; Yuan X
    Clin Cancer Res; 2020 Sep; 26(17):4542-4550. PubMed ID: 32561664
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Randomized Phase III KEYNOTE-181 Study of Pembrolizumab Versus Chemotherapy in Advanced Esophageal Cancer.
    Kojima T; Shah MA; Muro K; Francois E; Adenis A; Hsu CH; Doi T; Moriwaki T; Kim SB; Lee SH; Bennouna J; Kato K; Shen L; Enzinger P; Qin SK; Ferreira P; Chen J; Girotto G; de la Fouchardiere C; Senellart H; Al-Rajabi R; Lordick F; Wang R; Suryawanshi S; Bhagia P; Kang SP; Metges JP;
    J Clin Oncol; 2020 Dec; 38(35):4138-4148. PubMed ID: 33026938
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Second-line pembrolizumab versus chemotherapy in Japanese patients with advanced esophageal cancer: subgroup analysis from KEYNOTE-181.
    Muro K; Kojima T; Moriwaki T; Kato K; Nagashima F; Kawakami H; Ishihara R; Ogata T; Satoh T; Iwakami K; Han S; Yatsuzuka N; Takami T; Bhagia P; Doi T
    Esophagus; 2022 Jan; 19(1):137-145. PubMed ID: 34591237
    [TBL] [Abstract][Full Text] [Related]  

  • 12. First-line pembrolizumab and trastuzumab in HER2-positive oesophageal, gastric, or gastro-oesophageal junction cancer: an open-label, single-arm, phase 2 trial.
    Janjigian YY; Maron SB; Chatila WK; Millang B; Chavan SS; Alterman C; Chou JF; Segal MF; Simmons MZ; Momtaz P; Shcherba M; Ku GY; Zervoudakis A; Won ES; Kelsen DP; Ilson DH; Nagy RJ; Lanman RB; Ptashkin RN; Donoghue MTA; Capanu M; Taylor BS; Solit DB; Schultz N; Hechtman JF
    Lancet Oncol; 2020 Jun; 21(6):821-831. PubMed ID: 32437664
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Patient-reported outcomes following pembrolizumab or placebo plus pemetrexed and platinum in patients with previously untreated, metastatic, non-squamous non-small-cell lung cancer (KEYNOTE-189): a multicentre, double-blind, randomised, placebo-controlled, phase 3 trial.
    Garassino MC; Gadgeel S; Esteban E; Felip E; Speranza G; Domine M; Hochmair MJ; Powell S; Cheng SY; Bischoff HG; Peled N; Reck M; Hui R; Garon EB; Boyer M; Wei Z; Burke T; Pietanza MC; Rodríguez-Abreu D
    Lancet Oncol; 2020 Mar; 21(3):387-397. PubMed ID: 32035514
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Pembrolizumab plus chemotherapy versus placebo plus chemotherapy for previously untreated locally recurrent inoperable or metastatic triple-negative breast cancer (KEYNOTE-355): a randomised, placebo-controlled, double-blind, phase 3 clinical trial.
    Cortes J; Cescon DW; Rugo HS; Nowecki Z; Im SA; Yusof MM; Gallardo C; Lipatov O; Barrios CH; Holgado E; Iwata H; Masuda N; Otero MT; Gokmen E; Loi S; Guo Z; Zhao J; Aktan G; Karantza V; Schmid P;
    Lancet; 2020 Dec; 396(10265):1817-1828. PubMed ID: 33278935
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Pembrolizumab plus chemotherapy in Japanese patients with metastatic squamous non-small-cell lung cancer in KEYNOTE-407.
    Sugawara S; Tanaka K; Imamura F; Yamamoto N; Nishio M; Okishio K; Hirashima T; Tanaka H; Fukuhara T; Nakahara Y; Kurata T; Katakami N; Okada M; Horinouchi H; Udagawa H; Kasahara K; Satouchi M; Saka H; Tokito T; Hosomi Y; Aoe K; Kishi K; Ohashi K; Yokoyama T; Adachi N; Noguchi K; Schwarzenberger P; Kato T
    Cancer Sci; 2023 Aug; 114(8):3330-3341. PubMed ID: 37183528
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Pembrolizumab alone or in combination with chemotherapy as first-line therapy for patients with advanced gastric or gastroesophageal junction adenocarcinoma: results from the phase II nonrandomized KEYNOTE-059 study.
    Bang YJ; Kang YK; Catenacci DV; Muro K; Fuchs CS; Geva R; Hara H; Golan T; Garrido M; Jalal SI; Borg C; Doi T; Yoon HH; Savage MJ; Wang J; Dalal RP; Shah S; Wainberg ZA; Chung HC
    Gastric Cancer; 2019 Jul; 22(4):828-837. PubMed ID: 30911859
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Pembrolizumab for recurrent locally advanced or metastatic squamous cell carcinoma of the esophagus: a drug safety evaluation.
    Yamamoto K; Yamamoto S; Kato K
    Expert Opin Drug Saf; 2024 Jun; 23(6):667-675. PubMed ID: 38676380
    [TBL] [Abstract][Full Text] [Related]  

  • 18. First-line sugemalimab with chemotherapy for advanced esophageal squamous cell carcinoma: a randomized phase 3 study.
    Li J; Chen Z; Bai Y; Liu B; Li Q; Zhang J; Zhou J; Deng T; Zhou F; Gao S; Yang S; Ye F; Chen L; Bai W; Yin X; Cang S; Liu L; Pan Y; Luo H; Ji Y; Zhang Z; Wang J; Yang Q; Li N; Huang R; Qu C; Ni J; Wang B; Xu Y; Hu J; Shi Q; Yang J
    Nat Med; 2024 Mar; 30(3):740-748. PubMed ID: 38302715
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Pembrolizumab Plus Chemotherapy in Squamous Non-Small-Cell Lung Cancer: 5-Year Update of the Phase III KEYNOTE-407 Study.
    Novello S; Kowalski DM; Luft A; Gümüş M; Vicente D; Mazières J; Rodríguez-Cid J; Tafreshi A; Cheng Y; Lee KH; Golf A; Sugawara S; Robinson AG; Halmos B; Jensen E; Schwarzenberger P; Pietanza MC; Paz-Ares L
    J Clin Oncol; 2023 Apr; 41(11):1999-2006. PubMed ID: 36735893
    [No Abstract]   [Full Text] [Related]  

  • 20. Health-related quality-of-life analysis from KEYNOTE-590: pembrolizumab plus chemotherapy versus chemotherapy for advanced esophageal cancer.
    Mansoor W; Joo S; Norquist JM; Kato K; Sun JM; Shah MA; Enzinger P; Adenis A; Doi T; Kojima T; Metges JP; Li Z; Kim SB; Cho BC; Sunpaweravong P; Alsina M; Goekkurt E; Suryawanshi S; Shah S; Shen L
    Oncologist; 2024 Oct; 29(10):e1324-e1335. PubMed ID: 38815152
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 17.